This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

SafeCode Drug Technologies Receives Investment From Biomedix Ltd.

JERUSALEM, Jan. 6, 2013 /PRNewswire/ --  SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of a voice recognition drug administration safety application announced today that Israeli's Biomedix Ltd., (TASE: BMDX), a leading Medical Device/Biotech incubator has agreed to fund and purchase SAFC shares at 0.15 cents per share. Biomedix currently holds $200,000 USD worth of SafeCode Drug Technologies shares on its books.

Biomedix is an Israel-based, publicly-traded (TASE) Life Science focused (Israeli Medical Device & Biotech companies) investment management company. Key facts about Biomedix include:

  • Biomedix Group: Biomedix controls two of Israel's largest incubators: (ATI and Meytav), and a late-stage investment arm (SpearHead)
  • Focus on very early stage projects as well as managing later stage/mature companies
  • Attractive portfolio, high growth opportunities: OVER 50 PORTFOLIO COMPANIES ACROSS ALL CLINICAL & THERAPEUTIC FIELDS
  • Proven track record of deals & collaborations with leading global partners
  • Attractive deal flow pipeline
  • More information on Biomedix Ltd. can be found at http://www.biomedixincubator.com

Concurrently, SAFC has previously announced that the share Buyback Program, which was authorized by the Board Of Directors, will commence during the month of January 2013 and is expected to last approximately 1-3 months. The shares will be returned to the Treasury of the Company to be used for further issuances for future acquisitions of companies or technology applications in the medical industry. Funding for the acquisition of the shares will be subject to financing from third parties.

Under the program approved by the BOD, SafeCode Drug Technologies Corp is authorized to repurchase up to 1 million of its outstanding shares of common stock at a price up to $0.20 per share on the open market.

"SafeCode Drug Technologies Corp continues to progress its efforts to bring further added value to its shareholders," said Joel Klopfer, CEO of SafeCode Drug Technologies Corp. "The repurchase of shares and funding commitment from Biomedix will be used to enable us to acquire additional technologies that augment our existing commercial technology and/or additional drug safety applications in the medical industry, and we will be updating our shareholders in the forthcoming weeks of new and exciting news in regards to further acquisitions."

About SafeCode Drug Technologies

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,044.63 +13.49 0.08%
S&P 500 1,985.31 +1.18 0.06%
NASDAQ 4,509.88 -9.0220 -0.20%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs